EMAIL THIS PAGE TO A FRIEND

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

History. Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid. By Michael D. Loberg, Malcolm Cooper, Elizabeth Harvey, Patrick Callery, and William Faith. 1976.


PMID 6207277

Abstract

A new approach to radiopharmaceutical design is demonstrated, in which small chelating groups capable of binding gamma-emitting radiometals are attached to biologically active molecules, thus producing radiopharmaceuticals based on bifunctional drug and biochemical analogs. The chelating group iminodiacetic acid has been evaluated for this role by examining two N-substituted iminodiacetic acids: methyliminodiacetic acid (MIDA) and N-(2,6-dimethylphenylcarbamoylmethyl)iminodiacetic acid (HIDA). Radiochemical and biologic studies showed that both agents were obtained in high radiochemical purity, were stable in vitro and in vivo, and possessed biologic distributions governed almost exclusively by the N-substituted group. These characteristics of 99mTc-labled N-substituted iminodiacetic acids, prepared using an "instant kit" method, provide the basis for a valuable new class of radiopharmaceuticals based on bifunctional drug and biochemical analogs.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M51008
Methyliminodiacetic acid, 99%
C5H9NO4